Arcturus Therapeutics Holdings (ARCT) Net Cash Flow (2018 - 2026)

Arcturus Therapeutics Holdings (ARCT) has 9 years of Net Cash Flow data on file, last reported at -$19.4 million in Q1 2026.

• Quarterly Net Cash Flow rose 3.43% year-over-year to -$19.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$60.4 million (up 15.42% YoY) and the FY2025 annual result came in at -$61.1 million, down 11.17% from the prior year.
• Net Cash Flow fell to -$19.4 million in Q1 2026, from -$4.5 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $154.2 million in Q4 2022 to a low of -$63.9 million in Q1 2023.
• A 5-year average of -$9.4 million and a median of -$20.1 million in 2025 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow surged 455.47% — and 2025, when it sank 2867.33%.
• Tracing ARCT's Net Cash Flow over 5 years: stood at $154.2 million in 2022, then slumped by 113.07% to -$20.2 million in 2023, then surged by 99.26% to -$150000.0 in 2024, then slumped by 2867.33% to -$4.5 million in 2025, then sank by 335.65% to -$19.4 million in 2026.
• The last three Net Cash Flow figures came in at -$19.4 million (Q1 2026), -$4.5 million (Q4 2025), and -$16.1 million (Q3 2025), per Business Quant data.